ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 571,57
0,91%
Dow Jones
38 686,45
0,25%
DAX
18 068,21
0,26%
Brent Oil
83,33
1,47%
Bitcoin
66 035,25
-0,91%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ENDRA Life Sciences Inc (NDRA)

  7. ENDRA Life Sciences Inc (NDRA) Actualités

NDRA

ENDRA Life Sciences (NDRA)

ENDRA Life Sciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NDRA
DateHeureSourceTitreSymboleSociété
14/06/202422h01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NDRAENDRA Life Sciences Inc
12/06/202423h22Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:NDRAENDRA Life Sciences Inc
06/06/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
05/06/202414h20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NDRAENDRA Life Sciences Inc
05/06/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NDRAENDRA Life Sciences Inc
04/06/202415h21Business WireENDRA Life Sciences Announces Pricing of $8.0 Million Public OfferingNASDAQ:NDRAENDRA Life Sciences Inc
31/05/202422h21Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NDRAENDRA Life Sciences Inc
20/05/202414h00Business WireENDRA Provides Update Following In-person Meeting with FDANASDAQ:NDRAENDRA Life Sciences Inc
14/05/202422h26Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
14/05/202422h05Business WireENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
07/05/202414h00Business WireENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NDRAENDRA Life Sciences Inc
02/05/202414h00Business WireENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsNASDAQ:NDRAENDRA Life Sciences Inc
28/03/202421h05Business WireENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
21/03/202413h00Business WireENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024NASDAQ:NDRAENDRA Life Sciences Inc
27/02/202414h00Business WireENDRA Life Sciences Installs First TAEUS System in the UKNASDAQ:NDRAENDRA Life Sciences Inc
23/02/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NDRAENDRA Life Sciences Inc
21/02/202414h00Business WireNew ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS SystemNASDAQ:NDRAENDRA Life Sciences Inc
14/02/202414h30Business WireENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and EuropeNASDAQ:NDRAENDRA Life Sciences Inc
29/11/202314h00Business WireENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System TechnologyNASDAQ:NDRAENDRA Life Sciences Inc
27/11/202314h00Business WireENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor ConferenceNASDAQ:NDRAENDRA Life Sciences Inc
14/11/202322h05Business WireENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
08/11/202314h00Business WireENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New PatentsNASDAQ:NDRAENDRA Life Sciences Inc
07/11/202322h05Business WireENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:NDRAENDRA Life Sciences Inc
06/11/202314h00Business WireENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023NASDAQ:NDRAENDRA Life Sciences Inc
07/09/202314h00Business WireAbstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023NASDAQ:NDRAENDRA Life Sciences Inc
30/08/202314h00Business WireENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDANASDAQ:NDRAENDRA Life Sciences Inc
23/08/202314h00Business WireENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European PatentsNASDAQ:NDRAENDRA Life Sciences Inc
14/08/202322h53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NDRAENDRA Life Sciences Inc
14/08/202322h05Business WireENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
14/08/202319h30Business WireENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDANASDAQ:NDRAENDRA Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:NDRA

Dernières Valeurs Consultées

NASDAQ
AAPL
Apple
EU
EN
Bouygues
EU
DG
Vinci
EU
AI
Air Liquide
EU
BEL20
Bel 20
EU
HO
Thales
EU
ML
Michelin
EU
PX1
CAC 40
EU
GLE
Societe Generale
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés